Nxera Pharma Co., Ltd.
SOLTF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $86 | $80 | $87 |
| - Cash | $0 | $33 | $34 | $36 |
| + Debt | $0 | $65 | $66 | $68 |
| Enterprise Value | $1 | $117 | $111 | $119 |
| Revenue | $0 | $8 | $7 | $7 |
| % Growth | -99.5% | 27.2% | -3% | – |
| Gross Profit | $0 | $7 | $5 | $5 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| EBITDA | -$0 | $1 | -$1 | -$3 |
| % Margin | -26.7% | 6.3% | -16.7% | -40.5% |
| Net Income | -$0 | -$2 | -$1 | -$1 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS Diluted | -0.12 | -26.35 | -8.45 | -14.86 |
| % Growth | 99.5% | -211.8% | 43.1% | – |
| Operating Cash Flow | -$0 | -$0 | $1 | -$11 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $1 | -$11 |